萊美藥業(300006.SZ):萊美香港擬以299萬美元認購Replicor股份23萬股
格隆匯8月5日丨萊美藥業(300006.SZ)公佈,公司的全資子公司萊美(香港)有限公司(“萊美香港”)系公司海外創新技術和優質項目引進平台,萊美香港於2021年8月5日與Replicor Inc.(“Replicor”)共同簽署了《認購協議》。
根據《認購協議》約定,萊美香港擬以自有資金出資299萬美元(根據公吿披露日18點30分實時匯率計算,投資金額摺合人民幣約1932.1679萬元)向Replicor以13美元/股購買其23萬股普通股,同時,雙方有意在乙肝藥物中國市場的商業開發上開展更加廣泛的合作,包括在中國設立分支機構、推進在研產品在中國的臨牀研究、開發乙肝藥物中國市場等合作事項。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.